World News

Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference

Seegene Inc., South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at...

NeuroAiD(TM)II Holds Promise As A Safe Add-On Therapy to Standard Alzheimer Disease Symptomatic Treatments and May Have A Disease Modifying Effect by Delaying Disease Progression